Treatment of Cervical Cancer Stage IB1

Primary Treatment Approach

The National Comprehensive Cancer Network recommends radical hysterectomy with bilateral pelvic lymph node dissection as the primary treatment of choice for stage IB1 cervical cancer, offering excellent survival outcomes with 5-year disease-free survival exceeding 85% 1, 2.
Radical hysterectomy plus bilateral pelvic lymph node dissection is the standard surgical approach for stage IB1 disease, representing a Category 1 recommendation based on high-level evidence and uniform consensus 1, 2, 3, 4.
Para-aortic lymph node dissection (or sampling) is optional (Category 2B) but should be considered for larger tumors or when pelvic nodal disease is suspected 1, 2.
Sentinel lymph node (SLN) mapping can be considered as an alternative to complete pelvic lymphadenectomy, though this technique continues to be validated in prospective trials 1, 2.

Pelvic external beam radiation plus brachytherapy (total point A dose: 80-85 Gy) with or without concurrent cisplatin-based chemotherapy is an alternative option for patients who are medically inoperable, refuse surgery, or have contraindications to radical surgery 5, 6.

For patients desiring fertility preservation, radical trachelectomy with pelvic lymph node dissection (with or without para-aortic lymph node sampling) is an option, but this is typically restricted to carefully selected patients 1, 2.
Tumor size ≤2 cm is the most validated cutoff for fertility-sparing surgery in stage IB1 disease 3, 6.
Tumor location >1 cm from the internal cervical os is ideal, though some centers accept as close as 0.5 cm 7.

Observation is appropriate for patients with negative lymph nodes and no pathologic risk factors after radical hysterectomy 4.
Adjuvant pelvic radiation is recommended (Category 1) for patients with negative lymph nodes but who have at least two of the following intermediate-risk factors: deep stromal invasion (>1/3), lymphovascular space invasion (LVSI), 4, 6.
Postoperative pelvic radiation with concurrent cisplatin-containing chemotherapy (Category 1) is mandatory for patients with any of the following high-risk features: positive pelvic lymph nodes, positive surgical margins, positive parametrial involvement 4, 8.
The standard concurrent chemotherapy regimen is weekly cisplatin 40 mg/m² during external beam radiation, which has demonstrated significant improvements in overall survival for high-risk early-stage disease 9.

Avoid performing radical hysterectomy if lymph nodes are found to be positive intraoperatively—these patients should receive primary chemoradiation instead to avoid the increased morbidity of combined modality therapy 3, 4.
Do not use concurrent chemoradiation as primary treatment for stage IB1 disease unless the patient is not a surgical candidate—this approach has not been specifically studied in smaller IB1 tumors, and careful risk/benefit consideration is required 1, 2.
Pretreatment imaging with PET/CT can be performed to rule out extrapelvic disease before finalizing the treatment approach 1, 3.